Xolair 150 MG/ML syringeml
Ended Awarded
- Contract number
- SPE2DB25FCMYZ
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $3,095
Award facts
- Contract value 100% obligated
- $3,094.80 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $3,094.80 by the Defense Logistics Agency on August 27, 2025, for the supply of Xolair 150 mg/ml syringes. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of September 18, 2025, and carries no set-aside designation. This award is issued under DMS Pharmaceutical Group's larger single-award Indefinite Delivery Contract with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026, which authorizes the agency to issue delivery orders for comprehensive pharmaceutical products and medical supplies supporting Department of Defense healthcare facilities worldwide.
Xolair (omalizumab) is a biologic medication primarily used in the treatment of moderate-to-severe allergic asthma and chronic idiopathic urticaria. The Defense Logistics Agency utilizes its pharmaceutical supply contracts to ensure military medical treatment facilities have access to essential medications and biologics. DMS Pharmaceutical Group's role as a primary pharmaceutical distributor to federal healthcare systems positions it as a critical supplier within the defense medical supply chain, with this particular delivery order fulfilling near-term medication requirements for military healthcare operations.
Quick answers
Who was awarded contract SPE2DB25FCMYZ?
SPE2DB25FCMYZ was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on August 27, 2025.
How much is contract SPE2DB25FCMYZ worth?
The government has obligated $3,095 on SPE2DB25FCMYZ.
Is contract SPE2DB25FCMYZ an order under another contract?
Yes. SPE2DB25FCMYZ is a delivery order under SPE2DB24D9144, an indefinite delivery contract.
Was contract SPE2DB25FCMYZ competed?
The extent of competition for SPE2DB25FCMYZ was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award